Cassava sciences reports 2024 financial results and provides business update

Austin, texas, march 03, 2025 (globe newswire) -- cassava sciences, inc. (nasdaq: sava, “cassava”, the “company”), a clinical-stage biotechnology company focused on developing novel, investigational treatments for central nervous system (cns) disorders, including alzheimer's disease and tuberous sclerosis complex (tsc)-related seizures, today reported financial results for the year ended december 31, 2024 and provided a business update.
sava Ratings Summary
sava Quant Ranking